|
US7550143B2
(en)
*
|
2005-04-06 |
2009-06-23 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
US7666400B2
(en)
|
2005-04-06 |
2010-02-23 |
Ibc Pharmaceuticals, Inc. |
PEGylation by the dock and lock (DNL) technique
|
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
US7052686B2
(en)
|
2000-09-29 |
2006-05-30 |
Schering Corporation |
Pegylated interleukin-10
|
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
|
US7906118B2
(en)
|
2005-04-06 |
2011-03-15 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
|
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US20110064754A1
(en)
*
|
2005-03-03 |
2011-03-17 |
Center For Molecular Medicine And Immunology |
Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
|
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US8491914B2
(en)
*
|
2004-02-13 |
2013-07-23 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for delivery of interference RNA
|
|
US9481878B2
(en)
|
2004-02-13 |
2016-11-01 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8034352B2
(en)
*
|
2005-04-06 |
2011-10-11 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US8003111B2
(en)
*
|
2005-04-06 |
2011-08-23 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US8435539B2
(en)
*
|
2004-02-13 |
2013-05-07 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US8551480B2
(en)
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US20110020273A1
(en)
*
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
|
US8562988B2
(en)
*
|
2005-10-19 |
2013-10-22 |
Ibc Pharmaceuticals, Inc. |
Strategies for improved cancer vaccines
|
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
|
CN101171034B
(zh)
|
2005-03-03 |
2014-06-18 |
免疫医疗公司 |
人源化l243抗体
|
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
|
US8481041B2
(en)
|
2005-04-06 |
2013-07-09 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
|
|
US20080171067A1
(en)
*
|
2007-01-17 |
2008-07-17 |
Immunomedics, Inc. |
Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites
|
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
US9623115B2
(en)
|
2005-04-06 |
2017-04-18 |
Ibc Pharmaceuticals, Inc. |
Dock-and-Lock (DNL) Complexes for Disease Therapy
|
|
US8158129B2
(en)
*
|
2005-04-06 |
2012-04-17 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US9931413B2
(en)
|
2005-04-06 |
2018-04-03 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
CA2604032C
(en)
*
|
2005-04-06 |
2017-08-22 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
US8067006B2
(en)
|
2005-04-06 |
2011-11-29 |
Immunomedics, Inc. |
Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
|
|
US7846445B2
(en)
*
|
2005-09-27 |
2010-12-07 |
Amunix Operating, Inc. |
Methods for production of unstructured recombinant polymers and uses thereof
|
|
US7855279B2
(en)
*
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
US9862770B2
(en)
|
2005-10-19 |
2018-01-09 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
|
US20100226884A1
(en)
|
2009-01-20 |
2010-09-09 |
Immunomedics, Inc. |
Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
|
|
WO2012024223A2
(en)
*
|
2010-08-17 |
2012-02-23 |
Immunomedics, Inc. |
Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
|
|
US20100268055A1
(en)
*
|
2007-07-19 |
2010-10-21 |
Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University |
Self-Anchoring MEMS Intrafascicular Neural Electrode
|
|
CA2695374A1
(en)
*
|
2007-08-15 |
2009-02-19 |
Amunix, Inc. |
Compositions and methods for modifying properties of biologically active polypeptides
|
|
US9272029B2
(en)
|
2009-03-26 |
2016-03-01 |
Ibc Pharmaceuticals, Inc. |
Interferon lambada-antibody complexes
|
|
WO2010022225A1
(en)
*
|
2008-08-20 |
2010-02-25 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (dnl) vaccines for cancer therapy
|
|
ES2957546T3
(es)
|
2008-12-17 |
2024-01-22 |
Merck Sharp & Dohme |
Producción de mono- y di-PEG-IL10; y usos
|
|
US8703717B2
(en)
*
|
2009-02-03 |
2014-04-22 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
|
DK3178835T3
(da)
|
2009-02-03 |
2019-06-24 |
Amunix Pharmaceuticals Inc |
Forlængede rekombinante polypeptider og sammensætninger omfattende samme
|
|
US8680050B2
(en)
*
|
2009-02-03 |
2014-03-25 |
Amunix Operating Inc. |
Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
|
|
US9849188B2
(en)
|
2009-06-08 |
2017-12-26 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
|
WO2010144508A1
(en)
|
2009-06-08 |
2010-12-16 |
Amunix Operating Inc. |
Glucose-regulating polypeptides and methods of making and using same
|
|
CA2771999A1
(en)
*
|
2009-08-24 |
2011-03-10 |
Amunix Operating Inc. |
Coagulation factor vii compositions and methods of making and using same
|
|
EP2473187A4
(en)
*
|
2009-08-31 |
2015-09-16 |
Immunomedics Inc |
COMPOSITIONS AND METHODS FOR USE OF IMMUNOXINS WITH RANPIRNASE (RAP) WITH HIGH CYTOTOXIC ACTIVITY
|
|
CA2772572A1
(en)
*
|
2009-08-31 |
2011-03-03 |
Ibc Pharmaceuticals, Inc. |
Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof
|
|
WO2011034660A1
(en)
*
|
2009-09-16 |
2011-03-24 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
|
IN2012DN02692A
(enExample)
*
|
2009-11-05 |
2015-09-04 |
Ct Molecular Med & Immunology |
|
|
IN2012DN03354A
(enExample)
|
2009-12-02 |
2015-10-23 |
Immunomedics Inc |
|
|
EP2509629A4
(en)
*
|
2009-12-09 |
2013-06-26 |
Ibc Pharmaceuticals Inc |
DNL ("DOCK-AND-LOCK") COMPLEXES FOR INTERFERING RNA ADMINISTRATION
|
|
CN102665757A
(zh)
*
|
2009-12-09 |
2012-09-12 |
免疫医疗公司 |
通过双特异性抗体预靶向的用于细胞毒性药物的递送系统
|
|
US10822396B2
(en)
|
2009-12-15 |
2020-11-03 |
MuHyeon CHOE |
Repeat-chain for the production of dimer, multimer, multimer complex and super-complex
|
|
US20120259099A1
(en)
*
|
2009-12-15 |
2012-10-11 |
MuHyeon CHOE |
Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an adherend of a type specifically adhering to monomers
|
|
WO2011123830A2
(en)
|
2010-04-02 |
2011-10-06 |
Amunix Operating Inc. |
Alpha 1-antitrypsin compositions and methods of making and using same
|
|
EP2635300A4
(en)
*
|
2010-11-03 |
2014-04-02 |
Ibc Pharmaceuticals Inc |
DOCK-AND-LOCK (DNL) CONSTRUCTS FOR THERAPY AGAINST HUMAN IMMUNE WEAKAGE VIRUS (HIV)
|
|
EP2693887B1
(en)
|
2011-04-06 |
2020-10-28 |
The Board of Regents of the University of Texas System |
Modulating bacterial mam polypeptides in pathogenic disease
|
|
AU2012250924B2
(en)
|
2011-05-02 |
2017-05-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
US20130101664A1
(en)
|
2011-08-18 |
2013-04-25 |
Donald W. Kufe |
Muc1 ligand traps for use in treating cancers
|
|
EP2753644A1
(en)
|
2011-09-09 |
2014-07-16 |
Universiteit Utrecht Holding B.V. |
Broadly neutralizing vhh against hiv-1
|
|
EP2785382B1
(en)
*
|
2011-12-02 |
2019-01-02 |
IBC Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors
|
|
WO2013123457A1
(en)
|
2012-02-15 |
2013-08-22 |
Biogen Idec Ma Inc. |
Recombinant factor viii proteins
|
|
CN111548418A
(zh)
|
2012-02-15 |
2020-08-18 |
比奥贝拉蒂治疗公司 |
因子viii组合物及其制备和使用方法
|
|
CN104302408B
(zh)
|
2012-02-27 |
2016-12-14 |
阿穆尼克斯运营公司 |
Xten缀合组合物和制造其的方法
|
|
CN104363919A
(zh)
|
2012-06-01 |
2015-02-18 |
Ibc药品公司 |
具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物
|
|
AU2013302696B9
(en)
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
US10131712B2
(en)
|
2012-08-14 |
2018-11-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
US20150231241A1
(en)
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
KR101358330B1
(ko)
|
2012-09-26 |
2014-02-12 |
현대모비스 주식회사 |
차속 제어 장치, 이를 포함하는 차속 제어 시스템 및 그 제어 방법
|
|
CN107753954A
(zh)
|
2012-12-13 |
2018-03-06 |
免疫医疗公司 |
功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
|
|
US9789156B2
(en)
|
2013-03-11 |
2017-10-17 |
Dana-Farber Cancer Institute, Inc. |
Combination anti-human epidermal growth factor receptor 2 (anti-HER2) cancer therapy using mucin 1 (MUC1) peptides and hemotherapeutics
|
|
EP2986306A4
(en)
|
2013-04-18 |
2016-12-07 |
Armo Biosciences Inc |
METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
|
|
CA2914837A1
(en)
|
2013-06-17 |
2014-12-24 |
Armo Biosciences, Inc. |
Method for assessing protein identity and stability
|
|
US10548953B2
(en)
|
2013-08-14 |
2020-02-04 |
Bioverativ Therapeutics Inc. |
Factor VIII-XTEN fusions and uses thereof
|
|
US10010588B2
(en)
|
2013-08-30 |
2018-07-03 |
Armo Biosciences, Inc. |
Methods of using pegylated interleukin-10 for treating hyperlipidemia
|
|
CA2924520C
(en)
|
2013-11-01 |
2023-09-26 |
Ibc Pharmaceuticals, Inc. |
Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
|
|
KR20160079114A
(ko)
|
2013-11-11 |
2016-07-05 |
아르모 바이오사이언시스 인코포레이티드 |
질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
|
|
JP2017509587A
(ja)
|
2013-12-27 |
2017-04-06 |
ノーバス・インターナショナル・インコーポレイテッドＮｏｖｕｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ，Ｉｎｃ． |
エトキシル化界面活性剤
|
|
US10605810B2
(en)
*
|
2013-12-30 |
2020-03-31 |
University-Industry Cooperation Group Of Kyung Hee University |
Pincers comprising antibody and aptamer conjugated via a linker which binds to the same target material and use thereof
|
|
EA201691111A1
(ru)
|
2014-01-10 |
2017-01-30 |
Байоджен Ма Инк. |
Химерные белки фактора viii и их применение
|
|
ES2978993T3
(es)
|
2014-02-21 |
2024-09-23 |
Ibc Pharmaceuticals Inc |
Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2
|
|
CA2935748A1
(en)
|
2014-02-25 |
2015-09-03 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
|
WO2015187295A2
(en)
|
2014-06-02 |
2015-12-10 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
|
US9580495B2
(en)
|
2014-06-24 |
2017-02-28 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
|
PL3204018T3
(pl)
|
2014-10-07 |
2022-01-03 |
Immunomedics, Inc. |
Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
|
|
EP3206713A4
(en)
|
2014-10-14 |
2018-06-27 |
Armo Biosciences, Inc. |
Interleukin-15 compositions and uses thereof
|
|
AU2015336101A1
(en)
|
2014-10-22 |
2017-04-20 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
US10618970B2
(en)
|
2015-02-03 |
2020-04-14 |
Armo Biosciences, Inc. |
Method of treating cancer with IL-10 and antibodies that induce ADCC
|
|
IL254389B2
(en)
*
|
2015-03-11 |
2023-03-01 |
Nektar Therapeutics |
Polymer conjugates and the il–7 group
|
|
EP3286224A4
(en)
|
2015-04-22 |
2018-11-14 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
|
CN107614515B
(zh)
|
2015-05-28 |
2022-03-22 |
免疫医疗公司 |
用于抗hiv(人免疫缺陷病毒)疗法和/或疫苗的t20构建体
|
|
WO2016191587A1
(en)
|
2015-05-28 |
2016-12-01 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
|
PT3313443T
(pt)
|
2015-06-25 |
2023-08-30 |
Immunomedics Inc |
Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
|
|
PL3316885T3
(pl)
|
2015-07-01 |
2021-12-06 |
Immunomedics, Inc. |
Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
|
|
UA126016C2
(uk)
|
2015-08-03 |
2022-08-03 |
Біовератів Терапеутікс Інк. |
Злитий білок фактора іх
|
|
CA2995120A1
(en)
|
2015-08-25 |
2017-03-02 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
JP7299021B2
(ja)
|
2015-09-11 |
2023-06-27 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
生体関連の直交性サイトカイン／受容体ペア
|
|
US10669338B2
(en)
|
2016-06-17 |
2020-06-02 |
Immunomedics, Inc. |
Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
|
|
WO2018027223A1
(en)
|
2016-08-05 |
2018-02-08 |
Duke University |
Camkk2 inhibitor compositions and methods of using the same
|
|
KR20190090827A
(ko)
|
2016-12-02 |
2019-08-02 |
바이오버라티브 테라퓨틱스 인크. |
키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
|
|
CA3044082A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
|
CN107118269B
(zh)
*
|
2017-06-05 |
2020-12-01 |
北京交通大学 |
一种重组人il-24蛋白的peg修饰方法
|
|
US10584306B2
(en)
|
2017-08-11 |
2020-03-10 |
Board Of Regents Of The University Of Oklahoma |
Surfactant microemulsions
|
|
US12037382B2
(en)
|
2018-02-05 |
2024-07-16 |
Stichting Vu |
Inverse agonistic anti-US28 antibodies
|
|
WO2019183131A1
(en)
|
2018-03-19 |
2019-09-26 |
Bioventures, Llc |
Periostin antibodies and methods of using the same
|
|
KR102914074B1
(ko)
|
2018-05-18 |
2026-01-16 |
바이오버라티브 테라퓨틱스 인크. |
A형 혈우병의 치료 방법
|
|
US12128099B2
(en)
|
2018-05-25 |
2024-10-29 |
Bioventures, Llc |
Myxoma virus compositions and methods of use
|
|
WO2020080941A1
(en)
|
2018-10-16 |
2020-04-23 |
Umc Utrecht Holding B.V. |
Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
|
|
US12428626B2
(en)
|
2018-11-20 |
2025-09-30 |
Bioventures, Llc |
Cells for the production of viruses and methods of using the same
|
|
EP4004037A1
(en)
|
2019-07-26 |
2022-06-01 |
Vanderbilt University |
Human monoclonal antibodies to enterovirus d68
|
|
KR20220140568A
(ko)
|
2020-02-11 |
2022-10-18 |
벤더르빌트 유니버시티 |
중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단일클론 항체
|
|
WO2021195385A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
|
|
WO2021195418A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
|
|
CN118541392A
(zh)
|
2021-09-28 |
2024-08-23 |
准星生物医药有限公司 |
多种形式的分子复合物
|
|
US20250084155A1
(en)
|
2021-09-29 |
2025-03-13 |
Board Of Regents, The University Of Texas System |
Anti-hsp70 antibodies and therapeutic uses thereof
|
|
GB202204813D0
(en)
|
2022-04-01 |
2022-05-18 |
Bradcode Ltd |
Human monoclonal antibodies and methods of use thereof
|